Global Oncolytic Virus Cancer Immunotherapy Market Size, Status and Forecast 2020-2026

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Monoclonal Antibodies
  • 1.4.3 Checkpoint Inhibitors
  • 1.4.4 Oncoloytic Viral Therapies and Cancer Vaccines
• 1.5 Market by Application
  • 1.5.1 Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2020 VS 2026
  • 1.5.2 Lung Cancer
  • 1.5.3 Breast Cancer
  • 1.5.4 Colorectal Cancer
  • 1.5.5 Melanoma
  • 1.5.6 Prostate Cancer
  • 1.5.7 Head and neck Cancer
  • 1.5.8 Ovarian Cancer
  • 1.5.9 Pancreatic Cancer
  • 1.5.10 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends by Regions

• 2.1 Oncolytic Virus Cancer Immunotherapy Market Perspective (2015-2026)
• 2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Regions
  • 2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Share by Regions (2015-2020)
  • 2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Oncolytic Virus Cancer Immunotherapy Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Oncolytic Virus Cancer Immunotherapy Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Market Size
  • 3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2015-2020)
  • 3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
  • 3.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2019
• 3.3 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
• 3.4 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
• 3.5 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2015-2020)
• 4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2021-2026)

5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application (2015-2026)

• 5.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)
• 5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
• 6.2 Oncolytic Virus Cancer Immunotherapy Key Players in North America (2019-2020)
• 6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
• 6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
• 7.2 Oncolytic Virus Cancer Immunotherapy Key Players in Europe (2019-2020)
• 7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
• 7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

8 China

• 8.1 China Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
• 8.2 Oncolytic Virus Cancer Immunotherapy Key Players in China (2019-2020)
• 8.3 China Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
• 8.4 China Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
• 9.2 Oncolytic Virus Cancer Immunotherapy Key Players in Japan (2019-2020)
• 9.3 Japan Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
• 9.4 Japan Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
• 10.2 Oncolytic Virus Cancer Immunotherapy Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
• 10.4 Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

11 India

• 11.1 India Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
• 11.2 Oncolytic Virus Cancer Immunotherapy Key Players in India (2019-2020)
• 11.3 India Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
• 11.4 India Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
• 12.2 Oncolytic Virus Cancer Immunotherapy Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
• 12.4 Central & South America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

13Key Players Profiles

• 13.1 AstraZeneca
  • 13.1.1 AstraZeneca Company Details
  • 13.1.2 AstraZeneca Business Overview and Its Total Revenue
  • 13.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020))
  • 13.1.5 AstraZeneca Recent Development
• 13.2 Amgen
  • 13.2.1 Amgen Company Details
  • 13.2.2 Amgen Business Overview and Its Total Revenue
  • 13.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.2.5 Amgen Recent Development
• 13.3 F Hoffman-La Roche
  • 13.3.1 F Hoffman-La Roche Company Details
  • 13.3.2 F Hoffman-La Roche Business Overview and Its Total Revenue
  • 13.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.3.5 F Hoffman-La Roche Recent Development
• 13.4 Bristol-Myers Squibb
  • 13.4.1 Bristol-Myers Squibb Company Details
  • 13.4.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  • 13.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.4.5 Bristol-Myers Squibb Recent Development
• 13.5 Novartis AG
  • 13.5.1 Novartis AG Company Details
  • 13.5.2 Novartis AG Business Overview and Its Total Revenue
  • 13.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.5.5 Novartis AG Recent Development
• 13.6 Merck & Co., Inc.
  • 13.6.1 Merck & Co., Inc. Company Details
  • 13.6.2 Merck & Co., Inc. Business Overview and Its Total Revenue
  • 13.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.6.5 Merck & Co., Inc. Recent Development
• 13.7 Pfizer
  • 13.7.1 Pfizer Company Details
  • 13.7.2 Pfizer Business Overview and Its Total Revenue
  • 13.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.7.5 Pfizer Recent Development
• 13.8 Biovex
  • 13.8.1 Biovex Company Details
  • 13.8.2 Biovex Business Overview and Its Total Revenue
  • 13.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.8.5 Biovex Recent Development
• 13.9 Cell Genesys
  • 13.9.1 Cell Genesys Company Details
  • 13.9.2 Cell Genesys Business Overview and Its Total Revenue
  • 13.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.9.5 Cell Genesys Recent Development
• 13.10 Crusade Laboratories
  • 13.10.1 Crusade Laboratories Company Details
  • 13.10.2 Crusade Laboratories Business Overview and Its Total Revenue
  • 13.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
  • 13.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 13.10.5 Crusade Laboratories Recent Development
• 13.11 Genelux Corporation
  • 10.11.1 Genelux Corporation Company Details
  • 10.11.2 Genelux Corporation Business Overview and Its Total Revenue
  • 10.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
  • 10.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 10.11.5 Genelux Corporation Recent Development
• 13.12 Lokon Pharma
  • 10.12.1 Lokon Pharma Company Details
  • 10.12.2 Lokon Pharma Business Overview and Its Total Revenue
  • 10.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
  • 10.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 10.12.5 Lokon Pharma Recent Development
• 13.13 MultiVir
  • 10.13.1 MultiVir Company Details
  • 10.13.2 MultiVir Business Overview and Its Total Revenue
  • 10.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
  • 10.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
  • 10.13.5 MultiVir Recent Development

14Analyst's Viewpoints/Conclusions

15Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer